Approved Drugs for Postmenopausal Osteoporosis in the United States and Canada

Revised: June 15, 2015

(Providers should check the full prescribing information for appropriate dosages for the indication and any updates or information that is not provided here, such as warnings and contraindications.)

Active ingredient ***Indications***	**Product name(s)**	**Dosages**
Bisphosphonates (oral unless otherwise specified)		
Alendronate ***Treatment*** ***Prevention***	Fosamax Various generics Binosto*	Treatment: 70 mg/wk, 10 mg/d Prevention: 35 mg/wk or 5 mg/d Treatment: 70 mg/wk (effervescent)
Alendronate + vitamin D_3 ***Treatment***	Fosamax Plus D* Fosavance† Various generics†	70 mg + 2,800 IU/wk; 70 mg + 5,600 IU/wk
Risedronate (immediate release) ***Treatment*** ***Prevention***	Actonel Various generics	Treatment: 5 mg/d; 35 mg/wk; 75 mg on 2 consecutive d/mo; 150 mg/mo Prevention: 5 mg/d; 35 mg/wk
Risedronate (delayed release) ***Treatment***	Actonel DR† Atelvia*	35 mg/wk
Risedronate + calcium carbonate ***Treatment*** ***Prevention***	Actonel Plus Calcium†	35 mg/wk (day 1) + 1,250 mg Ca (days 2-7)
Ibandronate ***Treatment*** ***Prevention***	Boniva* Various generics*	150 mg/mo
Ibandronate injection* ***Treatment***	Boniva Injection*	3 mg every 3 mo IV

Continued on page 2

Continued from page 1

Etidronate and calcium carbonate† ***Treatment*** ***Prevention***	Didrocal†	400 mg/d oral tablet for 14 d followed by 1,250 mg calcium/d for 76 d
Zoledronic acid ***Treatment*** ***Prevention***	Reclast* Aclasta† Various generics	Treatment: 5 mg/y IV Prevention: 5 mg/2y IV Treatment: 5 mg/y IV Prevention: single infusion of 5 mg
Estrogen agonist/antagonist		
Raloxifene ***Treatment*** ***Prevention***	Evista	60 mg/d
Calcitonin		
Calcitonin-salmon nasal spray (rDNA origin) ***Treatment (>5 y postmenopause)***	Fortical*	200 IU/d
Calcitonin-salmon nasal spray (synthetic) ***Treatment (>5 y postmenopause)***	Various generics*	200 USP Salmon Calcitonin Units/d
Calcitonin-salmon injection* ***Treatment (>5 y postmenopause)***	Miacalcin*	100 IU every other day sc or IM
Parathyroid hormone		
Teriparatide ***Treatment***	Forteo	20 µg/d (maximum lifetime exposure 24 mo)
RANK ligand inhibitor		
Denosumab ***Treatment***	Prolia	60 mg every 6 mo sc

Continued on page 3

Continued from page 2

Estrogen-only (oral)		
17β-estradiol	Estrace[†] Various generics	0.5, 1.0, 2.0 mg/d
Conjugated estrogens ***Prevention***	Premarin	0.3, 0.45*, 0.625, 0.9,* 1.25 mg/d
Conjugated estrogens, CSD (synthetic) ***Prevention***	[Pr]pms-Conjugated estrogens, CSD[†] [Pr]C.E.S.[†]	0.3, 0.625, 0.9, 1.25 mg/d
Estropipate* ***Prevention***	Various generics	0.625 (0.75 estropipate), 1.25 (1.5), 2.5 (3.0), 5.0 (6.0) mg/d
Estrogen-only (transdermal)		
17β-estradiol patch ***Prevention (Exception in Canada: Climara 0.25 mg)***	Alora* Climara Estraderm[*] Estradot[†] Menostar* Minivelle* Vivelle-Dot* Various generics	0.025, 0.05, 0.075, 0.1 mg/d (twice/wk) 0.025, 0.0375,* 0.05, 0.06,* 0.075, 0.1 mg/d (once/wk) 0.05, 0.1 mg/d (twice/wk) 0.025, 0.0375, 0.05, 0.075, 0.1 mg/d (twice/wk) 0.014 mg/d (once/wk) 0.025, 0.0375, 0.05, 0.075, 0.1 mg/d (twice/wk) 0.025, 0.0375, 0.05, 0.075, 0.1 (twice/wk)

Continued on page 4

Continued from page 3

Estrogen-progestogen combinations		
Oral continuous-cyclic		
Conjugated estrogens + medroxyprogesterone acetate ***Prevention***	Premphase*	0.625 mg E + 5.0 mg P/d (2 tablets: E and E+P) (E alone days 1-14, E + P days 15-28)
Oral continuous-combined		
Conjugated estrogens (E) + medroxyprogesterone acetate (P) ***Prevention***	Prempro*	0.3 or 0.45 mg E + 1.5 mg P/d*; 0.625 mg E + 2.5 mg or 5.0 mg P/d
Ethinyl estradiol (E) + norethindrone acetate (P) ***Prevention***	femhrt*, femHRT Lo† femhrt*, femHRT†	2.5 µg E + 0.5 mg P/d 5 µg E + 1 mg P/d†
Oral intermittent combined		
17β-estradiol (E) + norethindrone acetate (P) ***Prevention***	Activella* Activelle LD† Activelle†	0.5 mg E + 0.1 mg P/d; 1 mg E + 0.5 mg P/d 0.5 mg E + 0.1 mg P 1 mg E + 0.5 mg P
17β-estradiol (E)+ norgestimate (P) (intermittent-combined) ***Prevention***	Prefest*	1 mg E and 1 mg E + 0.09 mg P (E alone for 3 d, followed by E = P for 3 d, repeated continuously)

Continued on page 5

Continued from page 4

Transdermal continuous combined		
17β-estradiol (E)+ levonorgestrel (P) ***Prevention (indication only in United States)***	Climara Pro	0.045 mg E + 0.015 mg P (once/wk)
Estrogen agonist/antagonist combination		
Conjugated estrogens (E) + bazedoxifene (P) ***Prevention***	Duavee	0.045 mg E + 20 mg bazedoxifene/d

*Available in the United States but not Canada.
†Available in Canada but not the United States.
Products not marked are available in both the United States and Canada.
IV = intravenous, sc = subcutaneous

Copyright © 2015 The North American Menopause Society